Stockreport

Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting [Financial Post (Toronto, ...

Theratechnologies Inc. - Common Shares  (THTX) 
PDF Author of the article: You can save this article by registering for free here . Or sign-in if you have an account. Part 3 of Phase 1 trial in advanced ovarian cance [Read more]